[go: up one dir, main page]

WO1992000090A1 - COMPOSITION ET TRAITEMENT A L'AIDE DE PEPTIDES BIOLOGIQUEMENT ACTIFS ET D'ANTIBIOTIQUES INHIBANT LA GYRASE d'ADN - Google Patents

COMPOSITION ET TRAITEMENT A L'AIDE DE PEPTIDES BIOLOGIQUEMENT ACTIFS ET D'ANTIBIOTIQUES INHIBANT LA GYRASE d'ADN Download PDF

Info

Publication number
WO1992000090A1
WO1992000090A1 PCT/US1991/004453 US9104453W WO9200090A1 WO 1992000090 A1 WO1992000090 A1 WO 1992000090A1 US 9104453 W US9104453 W US 9104453W WO 9200090 A1 WO9200090 A1 WO 9200090A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
antibiotic
amino acid
dna gyrase
composition
Prior art date
Application number
PCT/US1991/004453
Other languages
English (en)
Inventor
Barry Berkowitz
Original Assignee
Magainin Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Pharmaceuticals Inc. filed Critical Magainin Pharmaceuticals Inc.
Priority to JP91511793A priority Critical patent/JPH05507718A/ja
Publication of WO1992000090A1 publication Critical patent/WO1992000090A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • This invention relates to biologically active peptides and proteins , and more particularly to compositions and uses involving biologically active peptides or proteins and an antibiotic which inhibits DNA gyrasee , and in particular quinolone antibiotics such as ciprofloxacin.
  • composition which includes includes at least one biologically active amphiphilic peptide and/or biologically active protein ; and an antibiotic which inhibits DNA gyrase.
  • a process wherein there is administered to a host at least one biologically active amphiphilic peptide which is an ion channel forming peptide and/or biologically active protein; and an antibiotic which inhibits DNA gyrase.
  • An ion channel-forming peptide or protein or ionophore is a peptide or protein which increases the permeability for ions across a natural or synthetic lipid membrane.
  • B Christensen et al. PNAS Vol. 85 Pgs 5072-76 (July, 1988) describes methodology which indicates whether or not a peptide or protein has ion channel-forming properties and is therefore an ionophore.
  • an ion channel- forming peptide or ion channel forming protein is a peptide or protein which has ion channel- forming properties as determined by the method of Christensen et al.
  • An amphiphilic peptide is a peptide which includes both hydrophobic and hydrophilic peptide regions.
  • biologically active peptide or protein, and an antibiotic which inhibits DNA gyrase are administered to a host
  • biologically active peptide or protein and the antibiotic which inhibits DNA gyrase may be administered as a single composition or in separate compositions, and the single or separate compositions may include additional materials, actives and/or inactives, in addition to the peptide and/or protein and antibiotic which inhibits DNA gyrase.
  • the ion channel- forming peptides employed in the present invention are generally water soluble to a concentration of at least 20 mg/ml at neutral pH in water.
  • such peptides are non-hemolytic; i. e. , they will not rupture blood cells at effective concentrations .
  • the structure of such peptide provides for flexibility of the peptide molecule. When the peptide is placed in water, It does not assume an amphiphilic structure. When the peptide encounters an oily surface or membrane, the peptide chain folds upon itself into a rod- like structure.
  • such peptides have at least 16 amino acids, and preferably at least 20 amino acids. In most cases, such peptides do not have in excess of 40 amino acids.
  • DNA gyrase is an enzyme which is involved in the formation of bonds between individual coiling strands of replicating bacterial DNA
  • DNA gyrase is necessary for the normal replication of bacterial DNA, and, therefore, antibiotics which inhibit DNA gyrase inhibit the normal replication of bacterial DNA.
  • antibiotics which inhibit DNA gyrase include nalidixic acid, oxolinic acid, cinoxacin, and quinolone antibiotics which include ciprofloxacin, norfloxacin, ofloxacin, enoxacin, pefloxacin, lomefloxacin, fleroxacin, tosulfloxacin, temafloxacin, and rufloxacin.
  • the following structural formulae of representative examples of antibiotics which inhibit DNA gyrase are the following structural formulae of representative examples of antibiotics which inhibit DNA gyrase.
  • Nalidixic acid has the following structure:
  • Oxolinic acid has the following structure:
  • Ciprofloxacin has the following structure:
  • Norfloxacin has the following structure:
  • the antibiotic which inhibits DNA gyrase is a quinolone antibiotic, and most preferably, the quinolone antibiotic is ciprofloxacin.
  • the peptide or protein and the antibiotic which inhibits DNA gyrase are employed in amounts effective to inhibit and/or prevent and/or destroy the growth of a target cell.
  • the quinolone antibiotic potentiates the action of the peptide or protein, and the peptide or protein potentiates the action of the antibiotic which inhibits DNA gyrase.
  • potentiate means that the amount of antibiotic which inhibits DNA gyrase is effective to reduce the minimum effective concentration of the peptide or protein for inhibiting growth of a target cell and the amount of peptide or protein is effective to reduce the minimum effective concentration of the antibiotic which inhibits DNA gyrase for inhibiting growth of a target cell.
  • the peptide or protein is administered topically at a concentration of from .05% to 10%.
  • the peptide or protein is employed to provide peptide or protein dosages of from lmg to 500mg per kilogram of host weight.
  • the antibiotic which inhibits DNA gyrase in general, is used topically at a concentration of from 0.05% to 10%.
  • the antibiotic which inhibits DNA gyrase is generally employed in an amount of from 1.25 to 45mg per kilogram of host weight per day.
  • a combination of peptide or protein and antibiotic which inhibits DNA gyrase in accordance with the present invention is effective as an antibiotic, and may be employed to inhibit, prevent or destroy the growth or proliferation of microbes, such as bacteria.
  • compositions have a broad range of potent antibiotic activity against a plurality of microorganisms, including Gram-positive Gram -negative bacteria. Such compositions may be employed for treating or controlling microbial infection caused by organisms which are sensitive to such compositions.
  • the treatment may comprise administering to a host organism or tissues acceptable to or affiliated with a microbial infection an anti-microbial amount of such peptide or protein and antibiotic which inhibits DNA gyrase.
  • compositions may also be used as preservatives or sterilants for materials susceptible to microbial contamination .
  • compositions of the present invention may also be used in the treatment of external burns and to treat and/or prevent skin and burn infections.
  • the compositions may be used to treat skin and burn infections caused by organisms such as, but not limited to, P . aeruginosa and S. aureus.
  • compositions may also be used in the prevention or treatment of eye infections.
  • infections may be caused by bacteria such as , but not limited to, P. aeruginosa. S .auerus. and N . gonorrhoeae.
  • the peptide used in conjunction with the antibiotic which inhibits DNA gyrase is a basic (positively charged) polypeptide having at least sixteen amino acids wherein the polypeptide includes at least eight hydrophobic amino acids and at least eight hydrophilic amino acids.
  • the hydrophobic amino acids are in groups of two adjacent amino acids, and each group of two hydrophobic amino acids is spaced from another group of two hydrophobic amino acids by at least one amino acid other than a hydrophobic amino acid (preferably at least two amino acids) and generally by no greater than four amino acids , and the amino acids between pairs of hydrophobic amino acids may or may not be hydrophilic.
  • the hydrophilic amino acids are generally also in groups of two adjacent amino acids in which at least one of the two amino acids is a basic hydrophilic amino acid, with such groups of two hydrophilic amino acids being spaced from each other by at least one amino acid other than a hydrophilic amino acid (preferably at least two amino acids) and generally no greater than four amino acids, and the amino acids between pairs of hydrophilic amino acids may or may not be hydrophobic.
  • the polypeptide comprises a chain of at least four groups of amino acids, with each group consisting of four amino acids. Two of the four amino acids in each group are hydrophobic amino acids, and two of the four amino acids in each group are hydrophilic, with at least one of the hydrophilic amino acids in each group being a basic hydrophilic amino acid and the other being a basic or neutral hydrophilic amino acid.
  • the hydrophobic amino acids may be selected from the class consisting of Ala, Cys, Phe, Gly, He, Leu, Met, Val, Trp, and Tyr.
  • the neutral hydrophilic amino acids may be selected from the class consisting of Asn, Gin, Ser, and Thr.
  • the basic hydrophilic amino acids may be selected from the class consisting of Lys, Arg, His and ornithine (O) .
  • Each of the groups of four amino acids may be of the sequence ABCD, BCDA, CDAB, or DABC , wherein A and B are each hydrophobic amino acids and may be the same or different, one of C or D is a basic hydrophilic amino acid, and the other of C or D is a basic or neutral hydrophilic amino acid and may be the same or different.
  • the polypeptide chain may comprise 5 or 6 groups of this sequence .
  • each of A, B, C and D may be the same in some or all of the groups or may be different in some or all of the groups .
  • the polypeptide chain preferably has at least 20 amino acids , and no greater than 50 amino acids . It is to be understood, however, that the polypeptide does not have to consist entirely of the groups described above.
  • the polypeptide may have amino acids extending from either or both ends of the noted groups forming the polypeptide chain and/or there may be amino acids between one or more of the at least four groups and still remain within the scope of the invention.
  • the groups of amino acids may be repeating groups of amino acids or the amino acids in the various groups may vary provided that in each group of the at least four groups of amino acids there are two hydrophobic and two hydrophilic amino acids as hereinabove noted.
  • the biologically active polypeptide comprises a chain including at least four groups of amino acids, each containing four amino acids. Two of the four amino acids in each group are hydrophobic, at least one amino acid is basic hydrophilic, and the remaining one is basic or neutral hydrophilic, with the polypeptide chain preferably having at least 20 amino acids but no greater than 50 amino acids.
  • each of the at least four groups of amino acids which are in the peptide chain is of the sequence A-B-C-D, B-C-D- A, C-D-A-B or D-A-B-C wherein A and B are hydrophobic amino acids, one of C or D is a basic hydrophilic amino acid, and the other of C or D is basic or neutral hydrophilic amino acid.
  • the resulting polypeptide chain may have one of the following sequences:
  • X 1 is D; C-D- or B-C-D- , Y. is -A or -A-B or -A-B-C
  • X 2 is A- , D-A- or C-D-A- Y 2 is -B, -B-C or B-C-D
  • X 3 is B- , A-B- , D-A-BY 3 is -C , -C-D, -C-D-A
  • X 4 is C- , B-C- , A-B-C- Y 4 is -D, -D-A, -D-A-B
  • n is at least 4.
  • the peptide chain may include amino acids between the hereinabove noted groups of four amino acids provided that the spacing between such groups and the charge on the amino acids does not change the characteristics of the peptide chain which provide amphiphilicity and a positive charge and do not adversely affect the folding characteristics of the chain to that which is significantly different from one in which the hereinabove noted group of four amino acids are not spaced from each other.
  • the peptide may have amino acids extending from either end of the chain.
  • the chains may have a Ser-Lys sequence before th e "Ala” end, and/or an Ala-Phe sequence after the "Lys" end.
  • Other amino acid sequences may also be attached to the "Ala” and/or the "lys" end.
  • the chain may have , for example, a C-D sequence before the first A-B-C-D group .
  • other amino acid sequences may be attached to the "A" and/or the "D" end of one of these polypeptide chains.
  • the peptides may be produced by known techniques and obtained in substantially pure form.
  • the peptides may be synthesized on an automatic synthesizer. Journal of American Chemical Society, Vol. 85 Pages 2149-54(1963) . It is also possible to produce such peptides by genetic engineering techniques.
  • the peptide employed in conjunction with an antibiotic which inhibits DNA gyrase may be a magainin peptide.
  • a magainin peptide is either a magainin such as magainin I, II or III or an analogue or derivative thereof .
  • the magainin peptides preferably include the following basic peptide structure X 12
  • R 11 is a hydrophobic amino acid
  • R 12 is a basic hydrophilic amino acid
  • R 13 is a hydrophobic, neutral hydrophilic, or basic hydrophilic amino acid
  • R 14 and R 14a are hydrophobic or basic hydrophilic amino acids
  • R 15 is glutamic acid or aspartic acid, or a hydrophobic or a basic hydrophilic amino acid
  • n is 0 or 1.
  • R 13 is a hydrophobic or neutral hydrophilic amino acid
  • R 14a is a hydrophobic amino acid
  • R 15 is glutamic acid or aspartic acid.
  • a magainin peptide may include the following structure:
  • R 11 , R 12 , R 14 and R 14a are as previously defined.
  • a magainin peptide may also have the following structure:
  • R 16 where R 16 is a basic hydrophilic amino acid or asparagine or glutamine .
  • R 16 -R 17 where R 17 is a neutral hydrophilic amino acid, a hydrophobic amino acid, or a basic hydrophilic amino acid.
  • R 17 is a neutral hydrophilic amino acid.
  • a magainin peptide may also have the following structure :
  • the magainin peptides may also include the following basic peptide structure X 13 : - -R 14 -R 1 1 -R 14a -R 12 -R 1 1 -R 1 1 -R 12 -R 13 -
  • R 11 -R 14 -R 12 -R 1 1 -R 1 1 -R 12 - are amino acids as hereinabove described.
  • the magainin peptide may also include the following structure
  • R 17 (R 17 ) n wherein R 11 , R 14 , R 14a , R 15 , R 16 , and R 1 7 are as hereinabove described, and n is 0 or 1, and each n may be the same or different.
  • the magainin peptides generally include at least fourteen amino acids and may include up to forty amino acids.
  • a magainin peptide preferably has 22 or 23 amino acids. Accordingly, the hereinabove described basic peptide structures of a magainin peptide may include additional amino acids at the amino end or at the carboxyl end, or at both ends .
  • magainin peptides having the following primary sequence (expressed as a single letter code) as well as appropriate analogues and derivatives thereof :
  • the peptide employed in conjunction with an antibiotic which inhibits DNA gyrase may be a PGLa peptide or an XPF peptide .
  • a PGLa peptide is either PGLa or an analogue or derivative thereof
  • the PGLa peptides preferably include the following basic peptide structure X 14 :
  • R 11 -R 11 -R 12 - where R 11 , R 12 , R 1 4 , and R 17 are as previously defined.
  • the PGLa peptides generally include at least seventeen amino acids and may include as many as forty amino acids. Accordingly, the hereinabove described basic peptide structure for a PGLa peptide may include additional amino acids at the amino end or at the carboxyl end or at both the amino and carboxyl end.
  • a PGLa peptide may have the followin g structure:
  • a PGLa peptide may also have the following structure:
  • R 11 is as previously defined.
  • a PGLa peptide may also have the following structure:
  • An XPF peptide is either XPF or an analogue or derivative thereof
  • the XPF peptides preferably include the following basic peptide structure
  • R 11 , R 12 , R 14 , R 15 and R 17 are as Prevlously defined and R 18 is glutamine or asparagine or a basic hydrophilic, or hydrophobic amino acid and, n is 0 or 1.
  • the XPF peptides generally include at least nineteen amino acids and may include up to forty amino acids . Accordingly, the hereinabove described basic peptide structure of XPF may include additional amino acids at the amino end, or at the carboxyl end or at both the amino and carboxyl ends. Thus, for example, an XPF peptide may include the following structure:
  • R 11 and R 14 are as previously defined.
  • An XPF peptide may include the following structure :
  • An XPF peptide may also have the following structure:
  • XPF or PGLa peptides which are characterized by the following primary amino acid sequence (single letter amino acid code) :
  • the peptide employed in conjunction with an antibiotic which inhibits DNA gyrase may be a CPF peptide or appropriate analogue or derviative thereof .
  • CPF peptides as well as analogues and derivatives thereof are herein sometimes referred to collectively as CPF peptides.
  • the CPF peptide is preferably one which includes the following peptide structure X 30 :
  • R 21 is a hydrophobic amino acid
  • R 22 is a hydrophobic amino acid or a basic hydrophilic amino acid
  • R 23 is a basic hydrophilic amino acid
  • R 24 is a hydrophobic or neutral hydrophilic amino acid
  • R 25 is a basic or neutral hydrophilic amino acid.
  • hydrophobic amino acids are Ala, Cys, Phe, Gly, Ile, Leu, Met, Val, Trp, and Tyr.
  • the neutral hydrophilic amino acids are Asn, Gin, Ser, and Thr.
  • the basic hydrophilic amino acids are Lys, Arg, His, and ornithine.
  • the CPF peptide may include only the hereinabove noted amino acids or may include additional amino acids at the amino end or carboxyl end or both the amino and carboxyl end. In general, the peptide does not include more than 40 amino acids .
  • the CPF peptides including the above basic peptide structure may have from 1 to 4 additional amino acids at the amino end. Accordingly , such preferred peptides may be represented by the structural formula:
  • the carboxyl end of the basic peptide structure may also have additional amino acids which may range from 1 to 13 additional amino acids.
  • the basic structure may have from 1 to 7 additional amino acids at the carboxyl end, which may be represented follows:
  • X 30 is the hereinabove defined basic peptide structure and Z 30 is
  • R 21 -R 21 -R 24 -R 24 -R 26 -Gln (vi) R 21 -R 21 -R 24 -R 24 -R 26 -Gln; or (vii) R 21 -R 21 -R 24 -R 24 -R 26 -Gln-Gln,
  • R 21 and R 24 are as previously defined, and R 26 is proline or a hydrophobic amino acid.
  • Preferred peptides may be represented by the following structural formula:
  • CPF peptides which are useful in the present invention some of which have been described in the literature and comprise the following sequences (single letter amino acid code) :
  • CPF peptides which may be employed in the present invention are represented by the following (single letter amino acid code) : G12S3LG4ALKA5LKIG678LGG9(10)QQ
  • CPF peptide includes the basic peptide structure as well as analogs or derivatives thereof .
  • the biologically active peptide may include the following basic strucutre X 40 :
  • R 41 -R 42 -R 42 -R 43 -R 41 -R 42 -R 42 ] n wherein R 41 is a basic hydrophilic amino acid, R 42 is a hydrophobic amino acid, R 43 is a neutral hydrophilic or hydrophobic amino acid, and n is from 2 to 5.
  • such peptide may include the following structure :
  • Y 40 -X 40 wherein X 40 is as hereinabove described, and Y 40 is:
  • such peptide may include the following structure:
  • X 40 - Z 40 wherein X 40 is as hereinabove described, and Z 40 is:
  • such peptide may include the following structure:
  • n 3 or 3 or 4 or 5 or 6 or 7 or 8 or 10 or 11 or 12 or 13 or 14 or 15 or 14 or 15 or 16 or 15 or 16 or 16 or 17 or 18 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or 19 or 20 or
  • n 2
  • the peptide preferably is of the following structure as indicated by the single letter amino acid code:
  • the biologically active amphiphilic peptide may be a biologically active amphiphilic peptide including the following basic structure X 50 : R 41 -R 42 -R 42 -R 43 -R 4l -R 42 -R 42 -R 41 -R 42 -R 42 -R 42 -R 41 -R 42 -R 42 ,
  • R 41 , R 42 and R 43 are as hereinabove described.
  • such peptide may include the following structure:
  • Y 50 -X 50 wherein X 50 is as hereinabove described, and Y 50 is :
  • such peptide may include the following structure:
  • X 50 -Z 50 wnerein X 50 is as hereinabove described and Z 50 is :
  • the peptide may include the following structure: ( Y 50 )a-X 50- (Z 50 )b , wherein X and Y are as previously defined, a is
  • the peptide is of the following structural formula as indicated by the single letter amino acid code :
  • the peptide is of the following structural formula as indicated by the single letter amino acid code:
  • the peptide employed in conjunction with an antibiotic which inhibits DNA gyrase is a cecropin.
  • the cecroptns and analogs and derivatives thereof are described in Ann. Rev. Microbiol 1987 Vol. 41 pages 103-26 , in particular p . 108 and Christensen at al PNAS Vol. 85 p. 5072-76, which are hereby incorporated by reference.
  • cecropins includes the basic structure as well as analogues and derivatives.
  • the peptide employed in conjunction with an antibiotic which inhibits DNA gyrase is a sarcotoxin .
  • the sarcotoxins and analogs and derivatives thereof are described in Molecular Entomology pages 369-78 in particular p. 375 Alan R. Liss Inc . (1987) , which is hereby incorporated by reference.
  • sarcotoxin includes the basic materials as well as analogues and derivatives.
  • each of the amino acid residues of the biologically active amphiphilic peptide structures hereinabove described is a D- amino acid residue or a glycine residue.
  • an ion channel-forming protein may be used in conjunction with an antibiotic which inhibits DNA gyrase .
  • Ion channel- forming proteins which may be employed include defensins, also known as human neutrophil antimicrobial peptides (HNP) , major basic protein (MBP) of eosinophils, bactericidal permeability -increasing protein (BPI) , and a pore-forming cytotoxin called variously perforin, cytolysin, or pore-forming protein .
  • HNP human neutrophil antimicrobial peptides
  • MBP major basic protein
  • BPI bactericidal permeability -increasing protein
  • a pore-forming cytotoxin called variously perforin, cytolysin, or pore-forming protein .
  • Defensins are described in Selsted, et al. , J . Clin. Invest. . Vol. 76, pgs. 1436-1439 (1985) .
  • MBP proteins are described in Wasmoen, et al. ,
  • BPI proteins are described in Ooi, et al, J. Biol. Chem. . Vol . 262 , pgs. 14891-14894 (1987) .
  • Perforin is described in Henkart, et al. J. Exp. Med. , 160: 75 (1984) , and in Podack, et al. , J. Exp . Med. 160:695 (1984) .
  • the above articles are hereby incoroporated by reference.
  • ion channel-forming proteins includes the basic structures of the ion -forming proteins as well as analogues and derivatives.
  • CFU's colony forming units
  • P. aeruginosa strain 27853 or of P. aeruginosa strain 107 (which is gentamicin - resistant) dispersed in 100 ul of trypticase soy broth (TSB) were added to each of a series of test wells.
  • Either Peptide 1, Peptide 2, or Peptide 3 was added to each test well in increasing amounts from 0.25 to 256 ⁇ g/ml in absence of or in the presence of 20% of the minimal inhibitory concentration (MIC) of ciprofloxacin.
  • Peptide 1 is amide-terminated Magainin II
  • Peptide 2 is of the following structural formula:
  • Peptide 3 is of the following structural formula:
  • the MIC of ciprofloxacin alone against P. aeruginosa strain 27853 was l ⁇ g/ml, and against P. aeruginosa strain 107 was 2 ⁇ g/ml.
  • the MIC values for Peptides 1 , 2 and 3 either alone or in combination with 20% of the MIC of ciprofloxacin are given in Table I below.
  • microorganisms employed in the assays were grown according to the procedure described in Stutman, et al.
  • Examples 2 through 4 organisms were subcultured on agar plates, and then grown in trypticase soy broth (TSB) , or Mueller-Hinton broth. The final assays were then conducted in microtiter plates containing Mueller-Hinton broth 10 organisms were added to each well.
  • TTB trypticase soy broth
  • the minimal inhibitory concentrations (MIC's) of ciprofloxacin alone, of Peptide 1, as hereinabove described in Example 1 , alone, of ciprofloxacin when Peptide 1 was added (ciprofloxacin + Peptide 1) , and of Peptide 1 when ciprofloxacin was added, (Peptide 1 + ciprofloxacin) were tested against various isolates of strain MR- PSA Pseudomonas aeruginosa.
  • the second compound (or "+ " compound) dose to establish synergy was the lowest dose of the synerglzing drug which alone lacked antibacterial effect and was at least a 50% lower dose than the MIC for the synerglzing agent alone. The results are given below in Table 2.
  • the peptide or protein and antibiotic which inhibits DNA gyrase may be employed for treating a wide variety of hosts.
  • a host is an animal, and such animal may be a human or non-human animal.
  • the peptide or protein and the antibiotic which inhibits DNA gyrase may be employed together in a single composition, or in separate compositions .
  • the antibiotic which inhibits DNA gyrase and the peptide or protein may be delivered or administered in different forms, for example, the antibiotic which inhibits DNA gyrase may be administered systemically, while the peptide or protein may be administered topically.
  • the peptide or protein and/or antibiotic which inhibits DNA gyrase may be employed in a wide variety of pharmaceutical compositions in combination with a non- toxic pharmaceutical carrier or vehicle such as a filler, non -toxic buffer, or physiological saline solution .
  • a non- toxic pharmaceutical carrier or vehicle such as a filler, non -toxic buffer, or physiological saline solution .
  • Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule, or the like.
  • the peptide or protein and/or antibiotic which inhibits DNA gyrase may also be used in combination with adjuvants, protease inhibitors, or compatible drugs where such a combination is seen to be desirable or advantageous in controlling infection caused by harmful microorganisms, in particular bacteria .
  • the peptide(s) or protein(s) of the present invention may be administered to a host; in particular an animal, in an effective anti-microbial, in particular in an anti-bacterial amount, in conjunction with an antibiotic which inhibits DNA gyrase, for potentiating the activity of the peptide or protein.
  • the peptide could be administered in an amount of up to about 1% weight to weight and the antibiotic which inhibits DNA gyrase delivered in an amount of about 50 mM (about 0.1%) .
  • the antibiotic which inhibits DNA gyrase could be administered topically in conjunction with systemic administration of the peptide and/or protein.
  • the peptide or protein may be administered IV or IP to achieve a serum dose of 100 micrograms per milliliter (10 milligrams per kilogram) in conjunction with a topical dose of antibiotic which inhibits DNA gyrase of from about 4 ⁇ g/ml to about 100 ⁇ g/ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composition comprenant au moins un peptide ou une protéine amphiphile biologiquement actif, ledit peptide ou ladite protéine étant un peptide ou une protéine formant des canaux d'ions et un antibiotique inhibant la gyrase d'ADN . On peut administrer le peptide amphiphile biologiquement actif et l'antibiotique inhibant la gyrase d'ADN dans des doses efficaces pour inhiber la croissance d'une cellule cible telle qu'une bactérie.
PCT/US1991/004453 1990-06-27 1991-06-20 COMPOSITION ET TRAITEMENT A L'AIDE DE PEPTIDES BIOLOGIQUEMENT ACTIFS ET D'ANTIBIOTIQUES INHIBANT LA GYRASE d'ADN WO1992000090A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP91511793A JPH05507718A (ja) 1990-06-27 1991-06-20 生物活性ペプチドおよびｄｎａギラーゼを阻害する抗生物質よりなる組成物と治療法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54535690A 1990-06-27 1990-06-27
US545,356 1990-06-27

Publications (1)

Publication Number Publication Date
WO1992000090A1 true WO1992000090A1 (fr) 1992-01-09

Family

ID=24175898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004453 WO1992000090A1 (fr) 1990-06-27 1991-06-20 COMPOSITION ET TRAITEMENT A L'AIDE DE PEPTIDES BIOLOGIQUEMENT ACTIFS ET D'ANTIBIOTIQUES INHIBANT LA GYRASE d'ADN

Country Status (4)

Country Link
EP (1) EP0559647A1 (fr)
JP (1) JPH05507718A (fr)
CA (1) CA2045073A1 (fr)
WO (1) WO1992000090A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654274A (en) * 1992-06-01 1997-08-05 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107298A (en) * 1976-04-29 1978-08-15 Ab Bonnierforetagen Antigenically active polypeptide and a process for its preparation
US4617149A (en) * 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4636489A (en) * 1983-07-07 1987-01-13 Plantorganwerk Kg Modified protease inhibitors, process for their preparation, and pharmaceutical compositions prepared therefrom
US4659692A (en) * 1982-11-19 1987-04-21 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
US4668662A (en) * 1984-04-18 1987-05-26 Hoechst Aktiengesellschaft Polypeptides with an anticoagulant action, a process to prepare or obtain them, their use and agents containing them
US4791100A (en) * 1985-07-17 1988-12-13 Hoechst Aktiengesellschaft Novel polypeptides with a blood coagulation-inhibiting action, processes for their preparation and isolation, their use and agents containing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362209B1 (fr) * 1987-03-04 1994-06-08 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Composes bioactifs synthetiques nouveaux et procede d'obtention d'effets bioactifs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107298A (en) * 1976-04-29 1978-08-15 Ab Bonnierforetagen Antigenically active polypeptide and a process for its preparation
US4659692A (en) * 1982-11-19 1987-04-21 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
US4636489A (en) * 1983-07-07 1987-01-13 Plantorganwerk Kg Modified protease inhibitors, process for their preparation, and pharmaceutical compositions prepared therefrom
US4617149A (en) * 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4668662A (en) * 1984-04-18 1987-05-26 Hoechst Aktiengesellschaft Polypeptides with an anticoagulant action, a process to prepare or obtain them, their use and agents containing them
US4791100A (en) * 1985-07-17 1988-12-13 Hoechst Aktiengesellschaft Novel polypeptides with a blood coagulation-inhibiting action, processes for their preparation and isolation, their use and agents containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0559647A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654274A (en) * 1992-06-01 1997-08-05 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
US5686563A (en) * 1992-06-01 1997-11-11 Magainin Pharmaceuticals Inc. Biologically active peptides having n-terminal substitutions
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5763567A (en) * 1993-03-12 1998-06-09 Xoma Corporation Biologically active peptides from funcional domains of bactericidal/permeability-increasing protein and uses thereof

Also Published As

Publication number Publication date
JPH05507718A (ja) 1993-11-04
EP0559647A1 (fr) 1993-09-15
EP0559647A4 (fr) 1993-07-15
CA2045073A1 (fr) 1991-12-28

Similar Documents

Publication Publication Date Title
US5221664A (en) Composition and treatment with biologically active peptides and toxic cations
AU674525B2 (en) Biologically active peptides having N-terminal substitutions
EP0505497A1 (fr) Traitement des plaies utilisant des peptides biologiquement actifs
EP0469036B1 (fr) Composition et traitement utilisant des peptides biologiquement actifs et un antibiotique
US5208220A (en) Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase
US5217956A (en) Composition and treatment with biologically active peptides and certain anions
US5654274A (en) Biologically active peptides having N-terminal substitutions
WO1991012015A1 (fr) Peptides amphiphiles biologiquement actifs et procede pour inhiber la croissance de cellules cibles, de virus ou de cellules contaminees par virus
EP0590044A1 (fr) Composition de peptides biologiquement actifs presentant des substitutions au niveau de leur terminaison c et traitement a l'aide de ces peptides
AU3236293A (en) Composition and treatment with biologically active peptides and chelating agents
AU641129B2 (en) Composition and treatment with biologically active peptides and certain anions
WO1991016066A1 (fr) Compositions et traitement a base de peptides biologiquement actifs et de cations toxiques
AU693518B2 (en) Ion-channel forming amphiphilic peptides having n-terminal modifications
EP0533795A4 (en) Composition of and treatment with biologically active peptides having d-amino acid residues
WO1992000090A1 (fr) COMPOSITION ET TRAITEMENT A L'AIDE DE PEPTIDES BIOLOGIQUEMENT ACTIFS ET D'ANTIBIOTIQUES INHIBANT LA GYRASE d'ADN
EP0526570A1 (fr) Composition et traitement utilisant des peptides biologiquement actifs ainsi que des agents parasiticides et des agents fongicides
WO1999003488A2 (fr) Peptides biologiquement actifs a toxicite reduite chez l'animal et procedes d'elaboration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991912701

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991912701

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991912701

Country of ref document: EP